Cited by 633Clostridium difficile and Clostridium perfringens researchGastroesophageal reflux and treatmentsHelicobacter pylori-related gastroenterology studies

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression

Leonard, Jennifer, Marshall, John K., Moayyedi, Paul·2007·The American Journal of Gastroenterology

DOI 10.1111/j.1572-0241.2007.01275.x

Open this paper in CoChat — free account

Abstract

CONTEXT: Proton pump inhibitors (PPIs) and H(2) receptor antagonists (H(2)RAs) have become the mainstay of therapy in acid-related upper gastrointestinal disorders. There have been concerns raised about the possible association of PPIs with enteric infections. OBJECTIVE: We conducted a systematic review to evaluate any association between acid suppression and enteric infection. We also assessed differences between types of enteric infections and the type of acid suppression. DATA SOURCES: Electronic searches of MEDLINE (1966-2005), EMBASE (1988-2005), and CINAHL (1982-2005) were undertaken using a combination of subject headings and text words related to PPI therapy, H(2)RAs, and enteric infections. STUDY SELECTION: All observational studies were eligible, including cross-sectional, case control, and cohort studies that evaluated risk of enteric infection associated with antisecretory therapy. Eligibility assessment was made by two independent researchers. DATA EXTRACTION: Information on study design, patient population, type of acid suppression, type of infection, and outcomes was collected. The odds ratio (OR) of taking acid suppression therapy in cases and controls was calculated and results were synthesized using a random effects model (DerSimonian and Laird, Stats direct version 2.4.4). DATA SYNTHESIS: A total of 12 papers evaluating 2,948 patients with Clostridium difficile were included in the review. There was an increased risk of taking antisecretory therapy in those infected with C. difficile (pooled OR 1.94, 95% CI 1.37-2.75). There was significant heterogeneity between the studies (P= 0.0006) that was not explained by planned subgroup analysis. The association was greater for PPI use (OR 1.96, 95% CI 1.28-3.00) compared with H(2)RA use (OR 1.40, 95% CI 0.85-2.29). A total of six studies evaluated Salmonella, Campylobacter, and other enteric infections in 11,280 patients. There was an increased risk of taking acid suppression in those with enteric infections (OR 2.55, 95% CI 1.53-4.26). There was significant heterogeneity between the studies (P < 0.0001) that was not explained by subgroup analysis. The association was greater for PPI use (OR 3.33, 95% CI 1.84-6.02) compared with H(2)RA use (OR 2.03, 95% CI 1.05-3.92). CONCLUSION: There is an association between acid suppression and an increased risk of enteric infection. Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2007.01275.x

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and Mortality
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M., Michaud, S., Bourgault, A., Nguyen, T., Frenette, C. H., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,962
Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile –Associated Disease
Dial, S. (2005) · JAMA · doi:10.1001/jama.294.23.2989 · Cited by 954
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Laheij, R. J. F. (2004) · JAMA · doi:10.1001/jama.292.16.1955 · Cited by 879
A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use
Muto, C. A., Pokrywka, M., Shutt, K. A., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T. L., Croyle, K. S., Krystoflak, S., Patel-Brown, S., et al. (2005) · Infection Control and Hospital Epidemiology · doi:10.1086/502539 · Cited by 619
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies
Dial, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040876 · Cited by 577
Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding
Barkun, A. N., Bardou, M., Marshall, J. K., & for the Nonvariceal Upper GI Bleeding Consensus Conference Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00012 · Cited by 540

Show all 46 references

Research works printed but not linked: 4

Laheij RJ, JAMA, 2004, 1955
10.1001/archinte.146.1.95 · DOI
Gillis C, 2006, Gastroenterol, 20, 191
Rostom A, 2002, Cochrane Database Syst Rev, 4

Sorted by citations

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,371
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
Alhazzani, W. A., Møller, M. H., Arabi, Y. M., Loeb, M. B., Gong, M. N., Fan, E., Oczkowski, S. J. W., Levy, M. M., Derde, L. P. G., Dzierba, A. L., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004363 · Cited by 1,578
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
Interaction between drugs and the gut microbiome
Weersma, R. K., Zhernakova, A., & Fu, J. (2020) · Gut · doi:10.1136/gutjnl-2019-320204 · Cited by 1,028
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
The Changing Epidemiology of Clostridium difficile Infections
Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, A., Kuijper, E. J., & Wilcox, M. H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00082-09 · Cited by 838
Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis
Kwok, C. S., Arthur, A. K., Anibueze, C. I., Singh, S., Cavallazzi, R., & Loke, Y. K. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.108 · Cited by 579
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis
Janarthanan, S., Ditah, I., Adler, D. G., & Ehrinpreis, M. N. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.179 · Cited by 538
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D. P., Anand, S. S., Störk, S., Branch, K. R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.056 · Cited by 511
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 484
Control of Gastric Acid Secretion in Health and Disease
Schubert, M. L., & Peura, D. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.021 · Cited by 493
Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Salmonella infections in immunocompromised adults
Gordon, M. A. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.03.012 · Cited by 471
Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350
Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis
Lo, W., & Chan, W. W. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.011 · Cited by 353
Overutilization of proton-pump inhibitors: what the clinician needs to know
Heidelbaugh, J. J., Kim, A. H., Chang, R., & Walker, P. C. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12437358 · Cited by 342
Safety of the long-term use of proton pump inhibitors
Thomson, A. B. R. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i19.2323 · Cited by 314
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Sheen, E., & Triadafilopoulos, G. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1560-3 · Cited by 316
World Gastroenterology Organisation Global Guidelines
Hunt, R. H., Armstrong, D., Katelaris, P., Afihene, M., Bane, A., Bhatia, S. J., Chen, M., Choi, M., de Melo, A. C., Fock, K. M., et al. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000854 · Cited by 306
Proton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications
Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., Batard, E., Knights, D., & Montassier, E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14451 · Cited by 263
Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis
Trifan, A., Stanciu, C., Girleanu, I., Stoica, O. C., Singeap, A. M., Maxim, R., Chiriac, S. A., Ciobica, A., & Boiculese, L. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i35.6500 · Cited by 286
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015
Iwakiri, K., Kinoshita, Y., Habu, Y., Oshima, T., Manabe, N., Fujiwara, Y., Nagahara, A., Kawamura, O., Iwakiri, R., Ozawa, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1227-8 · Cited by 284
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q. C., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 309
The role of protein digestibility and antacids on food allergy outcomes
Untersmayr, E., & Jensen‐Jarolim, E. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.04.025 · Cited by 270
Mechanisms and therapeutic effectiveness of lactobacilli
Cerbo, A. D., Palmieri, B., Aponte, M., Morales‐Medina, J. C., & Iannitti, T. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202976 · Cited by 264
Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
Bruno, G., Zaccari, P., Rocco, G., Scalese, G., Panetta, C., Porowska, B., Pontone, S., & Severi, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i22.2706 · Cited by 258
Ranitidine is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns
Terrin, G., Passariello, A., Curtis, M. D., Manguso, F., Salvia, G., Lega, L., Messina, F., Paludetto, R., & Canani, R. B. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0796 · Cited by 255
Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer
Park, S.-Y., Hwang, B.-O., Lim, M., Ok, S.-H., Lee, S., Chun, K., Park, K.-K., Hu, Y., Chung, W., & Song, N. (2021) · Cancers · doi:10.3390/cancers13092124 · Cited by 247
Biology of Clostridium difficile: Implications for Epidemiology and Diagnosis
Karen C., C., & John G., B. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102824 · Cited by 233
C. difficile Infection: Changing Epidemiology and Management Paradigms
Vindigni, S. M., & Surawicz, C. M. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.24 · Cited by 239
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Side Effects of Long‐Term Proton Pump Inhibitor Use: A Review
Haastrup, P., Thompson, W., Søndergaard, J., & Jarbøl, D. E. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13023 · Cited by 231
Novel concepts in the pathophysiology and treatment of functional dyspepsia
Wauters, L. I., Talley, N. J., Walker, M. M., Tack, J. F., & Vanuytsel, T. (2019) · Gut · doi:10.1136/gutjnl-2019-318536 · Cited by 231
Systematic review: hypomagnesaemia induced by proton pump inhibition
Hess, M. W., Hoenderop, J. G. J., Bindels, R. J. M., & Drenth, J. P. H. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05201.x · Cited by 223
Invasive Non‐TyphiSalmonellaDisease in Africa
Morpeth, S. C., Ramadhani, H. O., & Crump, J. A. (2009) · Clinical Infectious Diseases · doi:10.1086/603553 · Cited by 219
Safety of Proton Pump Inhibitor Exposure
Yang, Y., & Metz, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.023 · Cited by 211
The Occurrence and Prevention of Foodborne Disease in Vulnerable People
Lund, B. M., & O’Brien, S. J. (2011) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2011.0860 · Cited by 215
Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis
Deshpande, A., Pant, C., Pasupuleti, V., Rolston, D. D. K., Jain, A., Deshpande, N., Thota, P., Sferra, T. J., & Hernández, A. V. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.09.030 · Cited by 211
Long-term Safety Concerns with Proton Pump Inhibitors
Ali, T., Roberts, D. N., & Tierney, W. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.014 · Cited by 197
The influence of proton pump inhibitors and other commonly used medication on the gut microbiota
Imhann, F., Vila, A. V., Bonder, M. J., Manosalva, A. G. L., Koonen, D. P. Y., Fu, J., Wijmenga, C., Zhernakova, A., & Weersma, R. K. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1284732 · Cited by 198
Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors
Almario, C. V., Chey, W. D., & Spiegel, B. M. R. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000798 · Cited by 190
Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health
Koch, C. D., Gladwin, M. T., Freeman, B. A., Lundberg, J. O., Weitzberg, E., & Morris, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.015 · Cited by 186
Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis
Eze, P., Balsells, E., Kyaw, M. H., & Nair, H. (2017) · Journal of Global Health · doi:10.7189/jogh.07.010417 · Cited by 186
Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety
Savarino, V., Mario, F. D., & Scarpignato, C. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.016 · Cited by 185
S2k-Leitlinie: Gastroösophageale Refluxkrankkheit unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
Koop, H., Fuchs, K., Labenz, J., Jansen, P. L., Messmann, H., Miehlke, S., Schepp, W., Wenzl, T., & der Leitliniengruppe, U. D. M. (2014) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1385202 · Cited by 172
A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors
Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Sargent, M., Laserna‐Mendieta, E. J., Claesson, M. J., & Targownik, L. E. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13568 · Cited by 166
Proton Pump Inhibitor Use in the U.S. Ambulatory Setting, 2002–2009
Rotman, S. R., & Bishop, T. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056060 · Cited by 168
Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI
Heidelbaugh, J. J., Goldberg, K. L., & Inadomi, J. M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.49 · Cited by 165
Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia
Johnstone, J., Nerenberg, K. A., & Loeb, M. B. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04284.x · Cited by 163
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection
Tariq, R., Singh, S., Gupta, A., Pardi, D. S., & Khanna, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.0212 · Cited by 160
Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota
von Rosenvinge, E. C., Song, Y., White, J. R., Maddox, C., Blanchard, T. G., & Fricke, W. F. (2013) · The ISME Journal · doi:10.1038/ismej.2013.33 · Cited by 154
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis
Rieder, F., Biancani, P., Harnett, K. M., Yerian, L. M., & Falk, G. W. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00454.2009 · Cited by 159
Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials
Alshamsi, F. E., Belley‐Côté, E. P., Cook, D., Almenawer, S. A., Alqahtani, Z., Perri, D., Thabane, L., Al‐Omari, A., Lewis, K. A., Guyatt, G. H., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1305-6 · Cited by 158
Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs
García-Mazcorro, J. F., Suchodolski, J. S., Jones, K. R., Clark‐Price, S. C., Dowd, S. E., Minamoto, Y., Markel, M. E., Steiner, J. M., & Dossin, O. (2012) · FEMS Microbiology Ecology · doi:10.1111/j.1574-6941.2012.01331.x · Cited by 150
Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis
Tleyjeh, I. M., Abdulhak, A. A. B., Riaz, M. A., Alasmari, F. A., Garbati, M. A., Alghamdi, M. A. A., Khan, A. R., Al-Tannir, M. A., Erwin, P. J., Ibrahim, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050836 · Cited by 148
Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer
Sáenz, J. B., & Mills, J. C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.5 · Cited by 138
Adverse Effects Associated with Proton Pump Inhibitor Use
Yibirin, M., Oliveira, D. D., Valera, R. J., Plitt, A. E., & Lutgen, S. (2021) · Cureus · doi:10.7759/cureus.12759 · Cited by 160
Proton pump inhibitors
Abraham, N. S. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328358d5b9 · Cited by 140
Proton pump inhibitor therapy and potential long-term harm
Corleto, V. D., Festa, S., Giulio, E. D., & Annibale, B. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000031 · Cited by 134
Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
Boursier, J., & Diehl, A. M. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004559 · Cited by 140
Adverse effects of proton pump inhibitor drugs: clues and conclusions
McCarthy, D. M. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32833ea9d9 · Cited by 132
Acid peptic diseases: pharmacological approach to treatment
Mejia, A. V., & Kraft, W. K. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.8 · Cited by 132
The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors
Minalyan, A., Gabrielyan, L., Scott, D. R., Jacobs, J. P., & Pisegna, J. R. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0577-6 · Cited by 134
Campylobacter epidemiology: a descriptive study reviewing 1 million cases in England and Wales between 1989 and 2011
Nichols, G. L., Richardson, J. F., Sheppard, S. K., Lane, C., & Sarran, C. E. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001179 · Cited by 127
Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection
Vincent, C., Stephens, D. A., Loo, V. G., Edens, T. J., Behr, M. A., Dewar, K., & Manges, A. R. (2013) · Microbiome · doi:10.1186/2049-2618-1-18 · Cited by 123
Effects of long-term PPI treatment on producing bowel symptoms and SIBO: PPI AND BOWEL SYMPTOMS AND SIBO ONSET
Compare, D., Pica, L., Rocco, A., De Giorgi, F., Cuomo, R., Sarnelli, G., Romano, M., & Nardone, G. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02419.x · Cited by 122
Gastrointestinal Complications of Cystic Fibrosis
Gelfond, D., & Borowitz, D. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.006 · Cited by 128
The risks of PPI therapy
Moayyedi, P., & Leontiadis, G. I. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.272 · Cited by 121
Safety of long-term PPI therapy
Reimer, C. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.06.001 · Cited by 119
Importance of gastrin in the pathogenesis and treatment of gastric tumors
Burkitt, M. D., Varró, A., & Pritchard, D. M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1 · Cited by 117
Micromotors for drug delivery in vivo: The road ahead
Srivastava, S. K., Clergeaud, G., Andresen, T. L., & Boisen, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.005 · Cited by 119
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study
Hart, E. J., Dunn, T. E., Feuerstein, S. G., & Jacobs, D. M. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2235 · Cited by 115
Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors
Hojo, M., Asahara, T., Nagahara, A., Takeda, T., Matsumoto, K., Ueyama, H., Matsumoto, K., Asaoka, D., Takahashi, T., Nomoto, K., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5122-4 · Cited by 114
Risk factors for complications and mortality of percutaneous endoscopic gastrostomy: a multicenter, retrospective study
Lee, C., Im, J. P., Kim, J. W., Kim, S., Ryu, D. Y., Cha, J. M., Kim, E. Y., Kim, E. R., & Chang, D. K. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-2979-3 · Cited by 114
Stress-Induced Ulcer Bleeding in Critically Ill Patients
Ali, T., & Harty, R. F. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.03.002 · Cited by 111
Toxicity of long-term use of proton pump inhibitors in children
Bruyne, P. D., & Ito, S. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2017-314026 · Cited by 111
Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis
Trikudanathan, G., Israel, J., Cappa, J., & O’Sullivan, D. M. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02650.x · Cited by 110
Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use
Naito, Y., Kashiwagi, K., Takagi, T., Andoh, A., & Inoüe, R. (2018) · Digestion · doi:10.1159/000481813 · Cited by 109
Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries
Krag, M., Perner, A., Wetterslev, J., Wise, M. P., Borthwick, M., Bendel, S., McArthur, C. J., COOK, D., Nielsen, N., Pelosi, P. P., et al. (2015) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12508 · Cited by 111
Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis
Huang, H., Jiang, W., Wang, C.-Y., Qin, H., & Du, B. (2018) · Critical Care · doi:10.1186/s13054-017-1937-1 · Cited by 114
Increased Rate of Spontaneous Bacterial Peritonitis Among Cirrhotic Patients Receiving Pharmacologic Acid Suppression
Goel, G., Deshpande, A., López, R., Hall, G. S., van Duin, D., & Carey, W. D. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.11.019 · Cited by 105
Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection
TURCO, R., Martinelli, M., Miele, E., Roscetto, E., Pezzo, M. D., Greco, L., & Staiano, A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04229.x · Cited by 104
Reported Side Effects and Complications of Long-term Proton Pump Inhibitor Use: Dissecting the Evidence
Johnson, D. A., & Oldfield, E. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.031 · Cited by 101
Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract – beyond the era of Helicobacter pylori
Walker, M. M., & Talley, N. J. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12666 · Cited by 103
Depression, antidepressant medications, and risk of Clostridium difficileinfection
Rogers, M. A. M., Greene, M. T., Young, V. B., Saint, S. K., Langa, K. M., Kao, J. Y., & Aronoff, D. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-121 · Cited by 101
The Efficacy of Proton Pump Inhibitors for the Treatment of Asthma in Adults
Chan, W. W., Chiou, E., Obstein, K. L., Tignor, A. S., & Whitlock, T. L. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.116 · Cited by 100
Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease
Choudhry, M., Soran, H., & Ziglam, H. M. (2008) · QJM · doi:10.1093/qjmed/hcn035 · Cited by 99
Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care
Ahrens, D., Behrens, G., Himmel, W., Kochen, M. M., & Chenot, J. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02973.x · Cited by 98
Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications
van Woerkom, M., Piepenbrink, H., Godman, B., de Metz, J., Campbell, S., Bennie, M., Eimers, M., & Gustafsson, L. L. (2012) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.12.52 · Cited by 97
Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms
Willems, R. P. J., van Dijk, K., Ket, J. C. F., & Vandenbroucke‐Grauls, C. M. J. E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0009 · Cited by 99
Recent advances in Clostridium difficile-associated disease
Monaghan, T. M., Boswell, T., & Mahida, Y. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2007.128157 · Cited by 95
Proton pump inhibitors increase significantly the risk ofClostridium difficileinfection in a low‐endemicity, non‐outbreak hospital setting
Dalton, B., LYE‐MACCANNELL, T., Henderson, E. A., MacCannell, D., & Louie, T. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03924.x · Cited by 94
Stress Ulcer Prophylaxis
Barletta, J. F., Bruno, J. J., Buckley, M. S., & Cook, D. J. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001872 · Cited by 97
Proton pump inhibitors and traditional nonsteroidal anti‐inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury
Leonard, C. E., Freeman, C. P., Newcomb, C. W., Reese, P. P., Herlim, M., Bilker, W. B., Hennessy, S., & Strom, B. L. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3329 · Cited by 92
Risk Factors Associated With Complications and Mortality in Patients With Clostridium difficile Infection
Morrison, R. H., Hall, N. S., Said, M., Rice, T., Groff, H. L., Brodine, S. K., Slymen, D. J., & Lederman, E. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir668 · Cited by 89
Proton Pump Inhibitor Use and Enteric Infections
Dial, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.46 · Cited by 90
Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients
Barletta, J. F., & Sclar, D. A. (2014) · Critical Care · doi:10.1186/s13054-014-0714-7 · Cited by 91
Complete Restriction of Fluoroquinolone Use to Control an Outbreak ofClostridium difficileInfection at a Community Hospital
Kallen, A. J., Thompson, A. D., Ristaino, P., Chapman, L., Nicholson, A. C., Sim, B.-T. T., Lessa, F. C., Sharapov, U. M., Fadden, E., Boehler, R., et al. (2009) · Infection Control and Hospital Epidemiology · doi:10.1086/595694 · Cited by 87

Authors: Leonard, J., Marshall, J. K., & Moayyedi, P.
Affiliations: McMaster University (CA)
ORCID: Marshall, John K.
Moayyedi, Paul
Venue: The American Journal of Gastroenterology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2007-09
Volume: 102
Issue: 9
Pages: 2047-2056
ISSN: 0002-9270 (ISSN-L)
1572-0241
DOI: 10.1111/j.1572-0241.2007.01275.x
OpenAlex: W2114271048
Cited by: 633
References: 46
Citations by year: 2026: 6 · 2025: 17 · 2024: 22 · 2023: 24 · 2022: 32 · 2021: 35 · 2020: 39 · 2019: 29 · 2018: 35 · 2017: 41 · 2016: 30 · 2015: 28 · 2014: 30 · 2013: 63 · 2012: 55
FWCI: 3.82
Type: journal article
Language: en
Open access: closed
Locations: The American Journal of Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
Keywords: acid suppression, proton pump inhibitors, H2 receptor antagonists, gastrointestinal infections, Clostridium difficile infection, Salmonella, Campylobacter, Clostridium difficile-associated diarrhea, antisecretory therapy, infection risk, drug safety, Helicobacter pylori, Helicobacter heilmannii
MeSH terms: Bacterial Infections, Gastric Acid, Gastrointestinal Diseases, Histamine H2 Antagonists, Humans, Risk Factors, Proton Pump Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks